Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best strong buy stocks to buy under $10. In a report released on July 25, Les Sulewski from Truist Financial maintained a Buy rating on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a price target of $8.00.

The rating update followed Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) announcement of certain unaudited preliminary financial results for fiscal Q2 on July 21. The company has plans to report the actual Q2 2025 results on August 5.

The unaudited preliminary financial results for the quarter showed a net revenue of $720 million to $730 million, suggesting an increase of around 3% versus the same period last year. Adjusted EBITDA rose around 13% to $180 million to $185 million, with income before income taxes of $45 million to $56 million, compared to $20 million in the same period in 2024.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company’s product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.

While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.